Monocyte chemoattractant protein-1 glycosaminoglycan-binding interface (MCP-1-GAG interface)

The Monocyte chemoattractant protein-1 (MCP-1/CCL2) glycosaminoglycan (GAG) binding interface is a specialized molecular site where the chemokine interacts with linear polysaccharides on cell surfaces and the extracellular matrix (UniProt P13500). This interaction is mediated by a cluster of basic amino acid residues on MCP-1, including Arg18, Lys19, and Arg24, which bind to the negatively charged sulfate groups of GAGs like heparan sulfate (PubMed: 12646618). Biologically, this binding is essential for the formation of haptotactic gradients that guide leukocytes toward inflammatory foci (PubMed: 15979983). Without GAG binding, MCP-1 is rapidly washed away by blood flow and fails to trigger the transendothelial migration of monocytes (PubMed: 12646618). In disease states, overactivity of this interface contributes to chronic inflammation, atherosclerosis, and tumor progression by facilitating continuous immune cell recruitment (PubMed: 16707701). Therapeutic targeting of this interface involves the use of GAG mimetics or decoy chemokines, such as PA401, that lack signaling capability but retain GAG-binding affinity (PubMed: 12646618). Such interventions aim to neutralize the chemokine gradient without necessarily blocking the signaling receptor (CCR2) directly. This approach offers a unique method for modulating the immune response in conditions like diabetic nephropathy and cardiovascular disease (PubMed: 24613441).

Other names

CCL2-GAG binding siteMCP-1 heparin-binding domainMonocyte chemoattractant protein-1 basic clusterMCP-1-GAG binding interface

Disruption of the chemokine-glycosaminoglycan interaction to prevent the formation of stable haptotactic gradients, thereby inhibiting leukocyte recruitment to sites of inflammation (PubMed: 12646618).